Intergalactic Therapeutics, a Boston, MA-based non-viral gene therapy platform, raised $75m in Series A financing.
ATP, a life sciences venture capital firm, made the founding investment.
Intergalactic’s breakthrough approach to non-viral gene therapy deploys two proprietary technologies: 1) C3DNA, covalently closed and circular DNA that does not integrate into the genome or lead to adverse immune reactions, permits large gene cargoes, and relies on a cell-free manufacturing process; and 2) COMET®, a clinically advanced, pulsed electric field focal gene therapy delivery system.
Led by Michael Ehlers, M.D., Ph.D., founder and Chief Executive Officer, Intergalactic Therapeutics is developing non-viral gene therapies in ophthalmology, oncology, and respiratory diseases. Potential applications of its technology platform in other areas include cardiology, hepatology, CNS, and musculoskeletal disorders.
To produce C3DNA, Intergalactic has developed a proprietary cell-free manufacturing process that avoids potential safety liabilities of more conventional gene therapy technologies and enables more patient doses to be made across more disease types.
The company recently entered into a five-year strategic partnership with Resilience, a differentiated provider of manufacturing solutions for next-generation medicines including cell and gene therapies, under which Resilience will provide cGMP capacity and resources to manufacture C3DNA products for Intergalactic’s first in human clinical trials, and process and analytical development support to advance Intergalactic’s novel cell-free manufacturing.
In addition to Dr. Ehlers, the Intergalactic Therapeutics leadership team includes:
- José Lora, Ph.D., Chief Scientific Officer.
- Eileen Higham, Ph.D., Senior Vice President, Technical Operations.
- Vincent Hennemand, Chief Operating Officer.
- Robert Farra, Chief Engineer.
FinSMEs
07/10/2021